Research Saves LivesNEW YORK, Nov. 27, 2017 /PRNewswire-USNewswire/ — Earlier this year, in an unprecedented, fast-tracked review, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) as the first immunotherapy treatment for advanced pancreatic cancer patients whose tumors are mismatch…



Source link